Regulatory & Legal Status
The legal status of peptides is fast-moving and easy to get wrong. This page explains the framework — FDA approval, compounding, sport bans, and what “research use only” actually means — in neutral terms. It is educational only and not legal or medical advice.
Everything here is date-stamped — verify before relying on it
Status as of 2026-06-07. FDA lists, compounding rules, and prohibited-substance lists change frequently, sometimes month to month. Always confirm the current status with primary sources (FDA, WADA) before acting on anything below.
FDA-approved vs research-only
The most important line is regulatory, not chemical (the same point made in What Are Peptides):
- FDA-approved drugs have passed clinical trials and are approved for specific uses, with defined dosing, manufacturing standards, and oversight. Examples on this wiki include Semaglutide, Tirzepatide, and Tesamorelin.
- Unapproved / “research-only” peptides have not been approved for human use. They are sold “for research use only” (RUO), frequently with little or no human clinical data. BPC-157, TB-500, and many others fall here.
A peptide being sold openly does not mean it is approved or legal to use as a drug. Approval status, not availability, is what defines the category.
Compounding: 503A and 503B
“Compounding” is the preparation of a customized medication by a pharmacy or facility, outside the normal mass-manufacturing approval pathway. Two sections of the Federal Food, Drug, and Cosmetic Act govern it:
- 503A pharmacies compound patient-specific prescriptions (traditional compounding).
- 503B outsourcing facilities can compound in larger batches under stricter manufacturing standards.
Compounders may only use bulk drug substances that the FDA permits. The FDA maintains evolving bulks lists that determine which substances can be compounded — and being left off, or placed in a restricted category, effectively bars a substance from legitimate compounding.
The 2025 GLP-1 compounding wind-down
During 2022–2024, surging demand put GLP-1 drugs on the FDA drug shortage list, which temporarily allowed compounders to make copies of Semaglutide and Tirzepatide. As supply recovered, the FDA declared the shortages resolved and set deadlines for compounders to stop:
- Tirzepatide shortage resolved (Dec 2024). Wind-down deadlines: 503A by Feb 18–19, 2025; 503B by Mar 19, 2025.
- Semaglutide shortage resolved (Feb 2025). Wind-down deadlines: 503A by Apr 22, 2025; 503B by May 22, 2025.
The Outsourcing Facilities Association challenged these determinations in federal court; courts denied preliminary injunctions and the deadlines held. In a further step, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely — announced April 30, 2026, with the notice published in the Federal Register on May 1, 2026 (finding no clinical need for outsourcing facilities to compound them from bulk; public comment open through June 29, 2026). The practical effect: large-scale compounded GLP-1s have been wound down, and patients relying on them have largely had to move to brand-name products or other options.
(Sources: U.S. FDA, “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List” (fda.gov, 2026-04-30); Federal Register notice 2026-08552 (2026-05-01); FDA drug-shortage and GLP-1 compounding press releases, 2025–2026.)
Peptides under FDA review — PCAC, July 23–24, 2026
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to advise whether seven popular peptides should be added to the 503A Bulks List (i.e., made eligible for traditional patient-specific compounding). Each is being considered as both free-base and acetate forms. Public comment docket: FDA-2025-N-6895 (comments by July 9, 2026 go to the committee; docket closes July 22, 2026).
| Day | Peptide | Use the FDA evaluated |
|---|---|---|
| Jul 23 | BPC-157 | Ulcerative colitis |
| Jul 23 | KPV | Wound healing & inflammatory conditions |
| Jul 23 | TB-500 | Wound healing |
| Jul 23 | MOTS-c | Obesity & osteoporosis |
| Jul 24 | DSIP (as “Emideltide”) | Opioid withdrawal, chronic insomnia, narcolepsy |
| Jul 24 | Semax | Cerebral ischemia, migraine, trigeminal neuralgia |
| Jul 24 | Epitalon | Insomnia |
Earlier (2023), the FDA had flagged several of these — including BPC-157 — under its interim 503A review as substances raising significant safety questions (immunogenicity, manufacturing impurities, sparse human safety data). The July 2026 meeting is the formal advisory step toward deciding their bulks-list status.
"Under review" ≠ approved or safe
PCAC makes non-binding recommendations; the FDA decides afterward. Being on the agenda means a peptide’s compounding status is unsettled — not that it has been blessed for human use. Adding a substance to the 503A bulks list would permit compounding, which is still not the same as FDA drug approval. These determinations can go either way and may change after this page’s date-stamp.
(Source: U.S. FDA, “July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee,” fda.gov advisory-committee calendar; docket FDA-2025-N-6895.)
Sport: WADA prohibited list
For competitive athletes, a separate and stricter rulebook applies: the World Anti-Doping Agency (WADA) Prohibited List (2026 edition in force). Many peptides on this wiki are banned, including:
- Growth hormone secretagogues / GHRPs — Ipamorelin, Hexarelin, CJC-1295, MK-677 (ibutamoren), and related compounds.
- GLP-1 / metabolic and peptide hormones — Semaglutide, Tirzepatide.
- Peptide fragments with biological activity — BPC-157, TB-500.
These fall under categories such as S0 (non-approved substances), S2 (peptide hormones, growth factors, related substances and mimetics), and S4 (hormone and metabolic modulators), and many are banned both in- and out-of-competition. Notably, S0 sweeps in any substance not approved by any health authority — so a brand-new, unapproved research peptide can be prohibited even if it is not named individually on the list.
(Source: WADA Prohibited List 2026, wada-ama.org.)
”Research use only” is not a legal shield
This is the single most misunderstood point in the space.
"Research use only / not for human consumption" does NOT make use legal
The FDA does not recognize a “research chemical” exemption that permits human use of unapproved drugs. Regulators look at intent: if a product is clearly marketed or set up for human use, the disclaimer is treated as void. The FDA has called such labels on injectable products a “ruse to avoid FDA scrutiny.”
Selling peptides alongside bacteriostatic water, syringes, or dosing guides, or making weight-loss / muscle / healing / anti-aging claims (including via testimonials), is treated as evidence of intent for human use — which exposes sellers to enforcement for misbranding and adulteration. FDA enforcement in this area has escalated, with numerous warning letters and some criminal referrals reported in 2025–2026.
The RUO label protects no one’s use of the product. It is a statement about a product’s regulatory status, not permission to inject it.
(Sources: FDA warning letters to peptide vendors; FDA statements and legal commentary on RUO labeling, 2025–2026.)
International variation
Legal status differs by country and can be stricter or looser than in the United States. A substance that is unscheduled in one jurisdiction may be a controlled or prescription-only medicine in another. Importing peptides can also trigger customs and import-law issues independent of whether the substance is “legal” to possess. Always check the rules for your own jurisdiction.
Bottom line
Summary (as of 2026-06-07)
- A few peptides are FDA-approved (Semaglutide, Tirzepatide, Tesamorelin, and — for one rare disease — SS-31); most discussed online are not.
- Compounded GLP-1s were wound down across 2025, with a 2026 FDA proposal to remove them from the 503B bulks list.
- Seven peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) have unsettled compounding status, headed to PCAC on July 23–24, 2026.
- Many peptides are banned in sport under WADA, including via the catch-all S0 category.
- “Research use only” is not a legal shield for human use.
- Status changes fast — re-verify before relying on any of this.
For how to evaluate suppliers and product quality (separate from legality), see Sourcing. None of this is legal advice; see the Disclaimer.
← Home · See the Disclaimer